Evotec Investor Presentation Deck

evotec Proteomics approach to targeted protein degradation Development of novel therapies for a broad range of diseases PAGE 16 Protein degradation partnership with BMS becomes strategic Using EVOpanOmics & EVOpanHunter - Quantum Leap in 2022 evotec & ll Bristol Myers Squibb May 2020 Screening milestone Mar 2021 Double-digit million extension 2018 Upfront US$ 65 m • Potential milestones 2019 > US$ 250 m per project • Double-digit royalties Oct 2020 Project initiation June 2020 US$ 10 m - Expansion 2020 Dec 2020 Second project initiation June 2021 New collaboration in undisclosed therapeutic area 2021 May 2021 Third project initiation May 2022 8-year extension Upfront $ 200 m Deal value > $ 5bn 2022

View entire presentation